Cargando…

Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series

OBJECTIVE: Assessement of the responder and non-responder rate to consecutive monoclonal CGRP-antibody (CGRP-mAb) treatment, the presence of side effects, analysis of predictors of response and loss-of-effectiveness evaluation over time. METHODS: We conducted a retrospective analysis including 171 p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaltseis, Katharina, Filippi, Vera, Frank, Florian, Eckhardt, Christine, Schiefecker, Alois, Broessner, Gregor
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10142255/ https://www.ncbi.nlm.nih.gov/pubmed/37118682 http://dx.doi.org/10.1186/s12883-023-03203-9

Ejemplares similares

Short Report of Longitudinal CGRP-Measurements in Migraineurs During a Hypoxic Challenge
por: Frank, Florian, et al.
Publicado: (2022)

Case report: Monoclonal CGRP-antibody treatment in a migraine patient with a mutation in the mitochondrial single-strand binding protein (SSBP1)
por: Kaltseis, Katharina, et al.
Publicado: (2022)

Hypoxia-related mechanisms inducing acute mountain sickness and migraine
por: Frank, Florian, et al.
Publicado: (2022)

Is prednisone still a reasonable option in the treatment of withdrawal headache in patients with chronic migraine and medication overuse headache in the age of CGRP antibodies? A narrative review
por: Kaltseis, Katharina, et al.
Publicado: (2022)

Migraine and aura triggered by normobaric hypoxia
por: Frank, Florian, et al.
Publicado: (2020)

Investigating the Migraine Cycle over 21 Consecutive Days Using Proton Magnetic Resonance Spectroscopy and Resting-State fMRI: A Pilot Study
por: Filippi, Vera, et al.
Publicado: (2022)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
por: Raffaelli, Bianca, et al.
Publicado: (2023)

The switcher and the scheduler
por: Arnault, C, et al.
Publicado: (1987)

CGRP measurements in human plasma – a methodological study
por: Messlinger, Karl, et al.
Publicado: (2021)

CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis
por: Frank, Florian, et al.
Publicado: (2021)

Inflammatory complications of CGRP monoclonal antibodies: a case series
por: Ray, Jason C., et al.
Publicado: (2021)

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
por: Straube, Andreas, et al.
Publicado: (2023)

What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
por: Waliszewska-Prosół, Marta, et al.
Publicado: (2023)

Effect of calcitonin gene-related peptide (-receptor) antibodies in chronic cluster headache: Results from a retrospective case series support individual treatment attempts
por: Ruscheweyh, Ruth, et al.
Publicado: (2020)

Phytohormones: plant switchers in developmental and growth stages in potato
por: Saidi, Abbas, et al.
Publicado: (2021)

Primary headache disorders in adolescents in North- and South-Tyrol: Findings of the EVA-Tyrol-Study
por: Kaltseis, Katharina, et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Mac OS X for Windows users: a switchers' guide
por: Coursey, David
Publicado: (2003)

HOX13 proteins: the molecular switcher in Hoxd bimodal regulation
por: Ros, Marian A.
Publicado: (2016)

The Factor H protein family: The switchers of the complement alternative pathway
por: Lucientes‐Continente, Laura, et al.
Publicado: (2022)

Methodological considerations on real-world evidence studies of monoclonal antibodies against the CGRP-pathway for migraine: a systematic review
por: Vandenbussche, Nicolas, et al.
Publicado: (2023)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

Immunological Drivers in Graves' Disease: NK Cells as a Master Switcher
por: Gallo, Daniela, et al.
Publicado: (2020)

A high‐throughput predictive method for sequence‐similar fold switchers
por: Kim, Allen K., et al.
Publicado: (2021)

Thymosin β4 Is an Endogenous Iron Chelator and Molecular Switcher of Ferroptosis
por: Lachowicz, Joanna I., et al.
Publicado: (2022)

Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study
por: Overeem, Lucas Hendrik, et al.
Publicado: (2023)

Neuroglucopenia and Metabolic Distress in Two Patients with Viral Meningoencephalitis: A Microdialysis Study
por: Kofler, Mario, et al.
Publicado: (2016)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
por: Mavridis, Theodoros, et al.
Publicado: (2021)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Language athletes: Dual-language code-switchers exhibit inhibitory control advantages
por: Gosselin, Leah, et al.
Publicado: (2023)

Non-responder migraine patients to a first anti-CGRP monoclonal antibody benefit from a switch to a second one
por: Fresán-Restituto, Daniel, et al.
Publicado: (2023)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

Preliminary specifications for the communications monitor and message switcher software in the PS multi-computer system
por: Carpenter, B
Publicado: (1973)

Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society
por: Diener, Hans-Christoph, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v21opgtg1b8rg00em7mqqclnj8